For example, the RELATIVITY-047 trial evaluating nivolumab plus the LAG-3 inhibitor relatlimab has shown promise in melanoma, and similar combinations are now being explored in HNSCC [12,121]. The gene discussed is LAG3; the disease is melanoma.